Sartorius Stedim Biotech Shares

Facts about the Share1)

Liquidity providerGilbert Dupont
Stock exchangeEuronext Paris
Market segmentLocal Securities – Compartiment A (Large Caps)
IndexesSBF 120; SBF 250; CAC All SHARES ; CAC MID & SMALL 190;
Number of shares92 180 190
thereof Sartorius AG
thereof free float
Voting rights162,041,944
thereof Sartorius AG
thereof free float

1) As of December 31, 2016

Share Markets Volatile on the Whole

Global stock markets were volatile again in the reporting year of 2016. In particular, the weak economic data of world’s largest economy, China, and development of oil prices caused the SBF120 to fall to its annual low of 3,084 points initially in February. Yet despite the British referendum on ending E.U. membership as well as the U.S. presidential elections, the continued expansive fiscal policy of the ECB enabled stock markets to recover substantially. On balance, the SBF120 reached an annual high of 3,836 points as of December 31, 2016, recording a gain of 4.7% in 2016. Following significantly above-average development over the past years, the NASDAQ Biotechnology Index fell 21.7%, which was attributed primarily to the discussion held on medical drug prices during the U.S. presidency election campaign.

Implementation of Stock Split

As a result of the significant three-digit level our share price, the Annual Shareholder’s Meeting decided on April 5, 2016, to split by 6 the par value of each of the company's shares. As a result, shareholders received 6 shares in exchange for each share held in. The reduction in the share price aims at increasing the tradability of Sartorius Stedim Biotech shares.

Stable Share Price Development

As the stock markets on the whole, the Sartorius Stedim Biotech share price showed a volatile development during the reporting period. After the price of the share had more than doubled in the previous year, it rose in the reporting year by 1.8% from €58.90 to 59.97€.

The share price hit its lowest closing price for the year of €51.17 on January 15, 2016. The highest closing price was registered on October 19, 2016, with €68.84.

Sartorius Stedim Biotech Share in €1)

January 1, 2012, to December 31, 2016

1) January 1, 2012, to May 9, 2016, adjusted for stock split

Sartorius Stedim Biotech Share1) in Comparison to the SBF 120, CAC MID & SMALL and NASDAQ Biotechnology Index (indexed)

January 1, 2016, to December 31, 2016

1) January 1, 2016, to May 9, 2016, adjusted for stock split

Investor Relations Activities

Sartorius Stedim Biotechs’ investor relations activities focus on maintaining an ongoing, open dialogue with shareholders, potential investors and financial analysts.

Besides providing first-half and annual reports as well as holding quarterly telephone conferences, we also regularly published press releases presenting the company business developments and other material events in the reporting year of 2016. Moreover, our management team was available to capital market participants on a regular basis at our sites in Goettingen and in Aubagne as well as at conferences and road shows for one-on-one meetings in international financial market centers such as London, Paris, Frankfurt am Main or New York. During the year under review, the communication focused in particular on explaining the update of our 2020 financial targets, current operating developments as well as the portfolio expansion following the acquisition of kSep.

All information and publications relating to our company and its shares may be found on our website at


The recommendations of financial analysts serve as an important foundation for the decisions of private and institutional investors when investing in shares. Currently, six institutions regularly prepare reports and updates on Sartorius Stedim Biotech shares.

Research Coverage

DateCompanyRecommendationTarget price in €
December 1, 2016Gilbert DupontAdd72.70
November 1, 2016EquitaHold68.00
October 24, 2016Oddo MidcapBuy70.00
October 24, 2016PortzamparcBuy70.00
October 24, 2016Société GénéraleBuy71.00
September 13, 2016JanneyHold70.00

Key Figures for Sartorius Stedim Biotech Share1)

Share price2) en €Reporting date59.9758.9026.8820.3112.23
Dividendes3) en €0.420.330.220.200.18
Total dividends paid3)
in millions of €
Payout ratio3,4) in %21.922.122.924.526.1
Dividend yield5) in %
Market capitalization
in millions of €
Average daily trading number
of shares
Trading volume of shares
in millions of €
(closing prices of the year)
SBF 120
(closing prices of the year)

1) For 2012 to 2015, share prices, dividends and average daily trading number of shares adjusted for stock split; rounded values

2) Daily closing price

3) For 2016, amounts suggested by the Board of Directors and subject to approval by the Annual General Shareholders' Meeting

4) Based on the underlying net result

5) Dividends in relation to the corresponding closing prices of the year

Sources: Euronext; Bloomberg


Sartorius Stedim Biotech strives to enable its shareholders to participate adequately in the company’s success and has continuously increased its dividend in recent years. In line with this objective, we basically follow the policy of paying out a relatively stable share of relevant net profit to our shareholders.

Relevant net profit

The Board of Directors will submit a proposal to the Annual General Shareholders' Meeting on April 4, 2017, to pay a dividend from the net profit of €176.6 million for fiscal 2016 of €0.42 per share compared to previous year’s figure of €0.33. The total profit distributed would increase by 26.0% from €30.7 million a year ago to €38.7 million. The corresponding dividend payout ratio would be 21.9% compared to 22.1% in the previous year. In relation to the shares' closing price of €59.97 on December 31, 2016, the dividend yield would be 0.7% (previous year: 0.6%).

Shareholder Structure

As a consequence of the stock split and the increase of the individual par value of the company's shares, Stedim Biotech S.A.’s issued capital amounted to €18.4 million as of December 31, 2016, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 162,041,944 voting rights as of the reporting date.

As of December 31, 2016, Sartorius AG holds 74.3% of the share capital and 84.5% of the outstanding voting rights. The remaining 25.7% of the shares are in free float; corresponding to 15.5% of the outstanding voting rights.